(Q34095231)

31 July 2017

1 reference

title

Cyclophosphamide and lupus nephritis: when, how, for how long? (English)

1 reference

31 July 2017

1 reference

Stella Ntali

1

1 reference

31 July 2017

George Bertsias

series ordinal

2

1 reference

31 July 2017

Dimitrios T Boumpas

series ordinal

3

1 reference

31 July 2017

1 June 2011

1 reference

Clinical Reviews in Allergy & Immunology

31 July 2017

1 reference

31 July 2017

40

1 reference

31 July 2017

3

1 reference

31 July 2017

181-191

1 reference

https://scigraph.springernature.com/pub.10.1007/s12016-009-8196-0

31 July 2017

0 references

cites work

Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

Treatment of Diffuse Proliferative Lupus Nephritis with Prednisone and Combined Prednisone and Cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

Adverse effects of therapy for ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

What's new in paediatric SLE?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

Intermittent intravenous cyclophosphamide therapy for lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

Induction therapy for pediatric focal proliferative lupus nephritis: cyclophosphamide versus mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

Long-term efficacy and safety of quadruple therapy in childhood diffuse proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

Acute renal failure in paediatric systemic lupus erythematosus: treatment and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

Successful treatment of class V+IV lupus nephritis with multitarget therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8196-0

Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy

21 January 2018

1 reference

12 December 2020

Cancer in systemic lupus: what drives the risk?

1 reference

12 December 2020

The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide

1 reference

12 December 2020

Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial

1 reference

12 December 2020

Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus

1 reference

12 December 2020

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

1 reference

12 December 2020

Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus

1 reference

12 December 2020

Outcomes of children with proliferative lupus nephritis: the role of protocol renal biopsy

1 reference

12 December 2020

Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis

1 reference

12 December 2020

The relationship of gonadal activity and chemotherapy-induced gonadal damage

1 reference

12 December 2020

Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial

1 reference

12 December 2020

European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies

1 reference

12 December 2020

Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide

1 reference

12 December 2020

Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide

1 reference

12 December 2020

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

1 reference

12 December 2020

Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus

1 reference

12 December 2020

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial

1 reference

12 December 2020

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

1 reference

12 December 2020

10.1007/S12016-009-8196-0

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference